|
Liver carcinoma
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
The inactivation of CDK7, BRD4, EP300, and MED1 selectively repressed the expression of SE-associated oncogenes in HCC.
|
30723918 |
2019 |
|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Of interest is that all HCC developing in PBP/MED1(DeltaLiv) mice were PBP/MED1 positive.
|
20007298 |
2010 |
|
Endometriosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis.
|
22138541 |
2012 |
|
Endometrioma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis.
|
22138541 |
2012 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity.
|
16109766 |
2005 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity.
|
16109766 |
2005 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity.
|
16109766 |
2005 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity.
|
16109766 |
2005 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity.
|
16109766 |
2005 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity.
|
16109766 |
2005 |
|
Cardiomyopathy, Dilated
|
0.210 |
AlteredExpression
|
group |
BEFREE |
Taken together, these data identify Med1 as an important regulator of vital cardiac gene expression and maintenance of normal heart function.<b>NEW & NOTEWORTHY</b> Disruption of transcriptional gene expression is a hallmark of dilated cardiomyopathy; however, its etiology is not well understood.
|
28159809 |
2017 |
|
Cardiomyopathy, Dilated
|
0.210 |
Biomarker
|
group |
MGD |
|
|
|
|
Heart failure
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Congestive heart failure
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Shared genetics of asthma and mental health disorders: a large-scale genome-wide cross-trait analysis.
|
31619474 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A covalent CDK7-specific inhibitor (THZ1) impairs AR-mediated MED1 recruitment to chromatin, and can suppress enzalutamide resistance <i>in vitro</i> and induce tumor regression in a castration-resistant prostate cancer xenograft model, suggesting a novel therapeutic approach for advanced prostate cancer.<i>See related article by Rasool et al., p. 1538</i>.
|
31676563 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
At the <i>in vivo</i> level, overexpression of miR-1291 inhibited the growth of xenograft tumors and significantly inhibited the expression of MED1 protein.
|
30867757 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MED1 mutation in its ER-interacting LxxLL motifs was sufficient to delay tumor onset and to impair tumor growth, metastasis, and cancer stem-like cell formation in this model.
|
29187405 |
2018 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using ZR-75-1 or BT-474 to generate in vivo tumor xenografts in BALB/c athymic mouse models, we showed that a combination of both drugs resulted in a stronger inhibition of tumor growth (P<0.05) and a greater decrease in the levels of activated MED1 (p-MED1) expressed in tumor issues compared with the use of either drug as a single agent.
|
28045951 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
89.5% of the HER2-amplified tumors were GRB7 and STARD3 co-amplified, whereas 68.4% of the HER2-amplified tumors had additional MED1 amplifications.
|
26910888 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, gene expression analysis uncovered networks highlighting S100A8, MMP1, and MED1 as promising candidate genes involved in high-grade and LVI-positive tumors.
|
25391423 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, these results suggest that miR-205 is an epigenetically regulated tumor suppressor that targets MED1 and may provide a potential biomarker in prostate cancer management.
|
22869146 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, knockdown of MED1 further potentiated tumor growth inhibition by fulvestrant.
|
23936234 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Notably, ectopic MED1 overexpression in prostate cancer xenografts significantly promoted tumor growth in nude mice.
|
23538858 |
2013 |